We are live on ! Find out more
SGTX

Sigilon Therapeutics, Inc. Common Stock
SGTX

Delisted

SGTX was delisted on the 10th of August, 2023.

Back to rankings

52 hedge funds and large institutions have $438M invested in Sigilon Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 14

16% more funds holding

Funds holding: 45 → 52 (+7)

18% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 11

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

53% less capital invested

Capital invested by funds: $942M → $438M (-$503M)

Holders
52
Holders Change
+7
Holders Change %
+15.56%
% of All Funds
0.91%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
21
Increased
9
Reduced
11
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$10.2M
2
BlackRock
BlackRock
New York
+$5.29M
3
APM
Avidity Partners Management
Texas
+$4.98M
4
JP Morgan Chase
JP Morgan Chase
New York
+$4.17M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$3.21M

Top Sellers

Rank Fund Capital Flow
1
MIM
Monashee Investment Management
Massachusetts
-$27M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$10.8M
3
SFM
Sphera Funds Management
Israel
-$6.28M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.38M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$2.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
WP
26
Woodline Partners
California
$764K +$54.1K +136 +5%
Squarepoint
27
Squarepoint
New York
$583K -$426K -1,071 -35%
Goldman Sachs
28
Goldman Sachs
New York
$439K -$470K -1,181 -44%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$386K +$528K +1,329 New
Deutsche Bank
30
Deutsche Bank
Germany
$352K +$482K +1,212 New
ZP
31
Zimmer Partners
New York
$335K – – –
Ensign Peak Advisors
32
Ensign Peak Advisors
Utah
$302K +$413K +1,038 New
N
33
Nuveen
North Carolina
$279K +$382K +961 New
California State Teachers Retirement System (CalSTRS)
34
California State Teachers Retirement System (CalSTRS)
California
$260K +$356K +896 New
LCM
35
Laurion Capital Management
New York
$224K – – –
Citadel Advisors
36
Citadel Advisors
Florida
$204K +$280K +704 New
Bank of America
37
Bank of America
North Carolina
$135K +$185K +465 New
New York State Common Retirement Fund
38
New York State Common Retirement Fund
New York
$65K +$88.3K +222 New
Wells Fargo
39
Wells Fargo
California
$54K +$73.5K +185 New
Morgan Stanley
40
Morgan Stanley
New York
$45K -$37K -93 -37%
SO
41
STRS Ohio
Ohio
$42K +$58K +146 New
UBS Group
42
UBS Group
Switzerland
$34K +$31K +78 +195%
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
$27K +$37.4K +94 New
HPC
44
HM Payson & Co
Maine
$23K – – –
TRCT
45
Tower Research Capital (TRC)
New York
$19K +$25.4K +64 New
Legal & General Group
46
Legal & General Group
United Kingdom
$17K +$23.9K +60 New
AIP
47
Ameritas Investment Partners
Nebraska
$14K +$19.1K +48 New
Citigroup
48
Citigroup
New York
$11K -$276K -694 -95%
Bank of Montreal
49
Bank of Montreal
Ontario, Canada
$5K +$7.95K +20 New
VFA
50
Valeo Financial Advisors
Indiana
$3K – – –
1
2
3

SGTX Hedge Fund Activity: Q1 2021 in Review

52 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q1 2021, worth a combined $438M — down 53% from $942M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new SGTX positions and 14 closed out — a net gain of 7 holders — while 9 added to existing stakes and 11 trimmed.

The largest buyer was Vanguard Group, adding an estimated $10.2M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $27M sold.

  • 52 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q1 2021, up from 45 in Q4 2020.
  • Funds reported $438M of Sigilon Therapeutics, Inc. Common Stock stock for Q1 2021, down 53% quarter-over-quarter.
  • 21 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q1 2021 and 14 closed out, a net change of +7 holders.
  • The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q1 2021 was Vanguard Group, an estimated $10.2M added.
  • The largest Sigilon Therapeutics, Inc. Common Stock seller in Q1 2021 was Monashee Investment Management, an estimated $27M sold.

Based on aggregated 13F filings for Q1 2021.